Market capitalization | $206.63m |
Enterprise Value | $17.65m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.24 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-141.65m |
Free Cash Flow (TTM) Free Cash Flow | $-78.07m |
Cash position | $188.98m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Cassava Sciences, Inc. forecast:
3 Analysts have issued a Cassava Sciences, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.23 -1.23 |
21%
21%
|
|
EBITDA | -140 -140 |
37%
37%
|
EBIT (Operating Income) EBIT | -142 -142 |
36%
36%
|
Net Profit | -18 -18 |
81%
81%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Head office | United States |
CEO | Richard Barry |
Employees | 29 |
Founded | 1998 |
Website | www.cassavasciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.